Loading organizations...
Beckley Psytech is an Oxford, United Kingdom-based clinical-stage biopharmaceutical company that develops short-acting psychedelic medicines to treat psychiatric and neurological conditions such as treatment-resistant depression. The organization focuses on optimizing synthetic compounds like 5-MeO-DMT and psilocin to create scalable, clinically approved pharmaceutical therapies for severe mental health disorders and alcohol use disorder. The enterprise has raised over $130 million in total funding across multiple financing rounds, including an $80 million Series B, securing venture capital from recognizable investors including Noetic Psychedelic Fund, Bail Capital, Jim Mellon, and Richard Reed. In early 2024, the firm secured a $50 million strategic investment from atai Life Sciences, which subsequently led to a 2025 merger between the two entities to form a new company called AtaiBeckley. Beckley Psytech was founded in 2019 by Cosmo Feilding Mellen and Amanda Feilding.
Beckley Psytech has raised $148.8M across 3 funding rounds.
Beckley Psytech has raised $148.8M in total across 3 funding rounds.
# Beckley Psytech: A Biopharmaceutical Company, Not a Technology Company
Beckley Psytech is a clinical-stage biopharmaceutical company, not a technology company. The premise of your query contains an inaccuracy. Beckley Psytech develops psychedelic-based pharmaceutical medicines for neurological and psychiatric disorders, positioning it within the biotech and pharmaceutical sector rather than the technology industry.
Founded in 2019, Beckley Psytech is a for-profit biopharmaceutical company dedicated to developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines[4]. The company emerged from a strategic partnership with the Beckley Foundation, a renowned non-profit NGO with a 20-year track record of advancing scientific research into psychedelic medicine[4].
In 2025, Beckley Psytech merged with atai Life Sciences to form AtaiBeckley, a global leader in developing transformative mental health therapies[1]. The combined entity focuses on creating effective, rapid-acting and convenient treatments for difficult-to-treat mental health conditions, with current emphasis on depression and substance use disorders[2]. The company addresses a critical global need: more than one billion people live with a mental health condition worldwide, yet most do not have access to effective care[3].
Beckley Psytech's founding in 2019 was rooted in recognizing the unrealized potential of psychedelic medicines as treatments for intractable, chronic mental and neurological conditions[4]. The company leveraged its partnership with the Beckley Foundation—which had spent two decades researching psychedelic medicine—to transform under-researched psychedelic agents into fully licensed medicines[4].
The strategic 2025 merger with atai Life Sciences represented a pivotal moment, combining Beckley Psytech's psychedelic medicine expertise with atai's broader mental health drug development capabilities. This combination created a more comprehensive platform for advancing mental health innovation at scale[1].
Beckley Psytech operates at the intersection of a significant market opportunity and a paradigm shift in mental health treatment. The global economic cost of mental health conditions is expected to reach $5 trillion by 2030, creating substantial demand for innovative solutions[3]. Psychedelic-assisted therapies represent an emerging treatment paradigm with potential to address the limitations of existing psychiatric medications.
The company's timing is strategic: regulatory pathways for psychedelic medicines are evolving, scientific evidence supporting their efficacy is accumulating, and investor interest in mental health innovation is growing. By combining rigorous clinical development with a comprehensive care model, AtaiBeckley is positioned to influence how psychedelic medicines are integrated into mainstream medical practice[5].
AtaiBeckley is advancing a differentiated approach to mental health treatment by developing psychedelic-based medicines alongside the clinical infrastructure needed for their safe and effective delivery. The merger with atai Life Sciences provides greater resources and scale to accelerate clinical trials and commercialization.
The company's success will depend on navigating regulatory approval pathways, demonstrating clinical efficacy in Phase 2 and Phase 3 trials, and building the psychotherapist training ecosystem required for treatment delivery. As mental health treatment paradigms shift toward rapid-acting, evidence-based alternatives to traditional pharmaceuticals, AtaiBeckley's integrated approach to medicine and psychotherapy could reshape how severe mental health conditions are treated globally.
Beckley Psytech has raised $148.8M in total across 3 funding rounds.
Beckley Psytech's investors include Christian Angermayer, Jay Newmark, re.Mind Capital, Satori Capital, What If Ventures, Adage Capital Management, Bicycle Day Ventures, Delphi VC, Leafy Tunnel, Negev Capital, Palo Santo, Amy Kruse.
Beckley Psytech has raised $148.8M across 3 funding rounds. Most recently, it raised $50.0M Other Equity in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 4, 2024 | $50M Venture Round | Christian Angermayer | — | Announced |
| Aug 1, 2021 | $80M Series B | JAY Newmark | Re.Mind Capital, Satori Capital, What IF Ventures, Adage Capital Management, Bicycle DAY Ventures, Delphi VC, Leafy Tunnel, Negev Capital, Palo Santo, AMY Kruse | Announced |
| Dec 23, 2020 | $18.8M Venture Round | — | Bail Capital, Noetic Fund | Announced |
